MolMed S.p.A. (MLM.MI) presented, at the 37th ESMO Congress, three studies on its investigational biological drug NGR-hTNF, including updated results in non-small cell lung cancer (NSCLC) patients and two retrospective analyses evaluating potential predictors of outcome in patients enrolled in Phase I and Phase II trials. Long-term efficacy analysis confirms the potential clinical benefit in lung […]